• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Nevro announces CEO succession plan, preliminary Q4 results

Nevro announces CEO succession plan, preliminary Q4 results

January 9, 2023 By Sean Whooley

D. Keith Grossman Nevro
[Image from LinkedIn]
Nevro (NYSE:NVRO) today announced that Chair, CEO and President D. Keith Grossman intends to retire this year.

Grossman informed the board that he plans to retire from his CEO and president duties in 2023. He intends to do so following the selection of his successor at the spinal cord stimulation (SCS) technology developer.

Following the CEO succession, Grossman plans to continue to serve as chair of Nevro’s board. The board commenced a targeted search process for a new CEO with assistance from a leading executive search firm.

Grossman has spent nearly 40 years as an executive in the medical device industry.

“I’m extremely proud of the significant progress we have made over the past four years, and I believe now more than ever Nevro is well-positioned for future growth and poised to enter an exciting period of progress,” Grossman said. “With what we believe will be continued recovery in our markets, important new products like the HFX iQ platform, entirely new patient populations such as PDN and NSBP, and the opportunity for attractive operating leverage on future growth as a result of our intense focus on the scalability of our expense structure, the outlook for Nevro is very bright.”

Nevro reports preliminary Q4 results, sets guidance

Redwood City, California-based Nevro expects fourth-quarter revenues to total approximately $113.8 million. That represents an 11% increase compared to the same quarter last year. Approximately $99.8 million in revenues came in through U.S. sales. Analysts expect Nevro to report $112.6 million in sales.

The company attributed the growth to its limited market release for the HFX iQ system. It received FDA approval in October.

It expects full-year sales to total approximately $406.4 million for a 5% increase over 2021.

Nevro projected its 2023 revenues to fall between $445 million and $455 million for a 10%-12% increase year-over-year. That guidance assumes 2023 includes steady recovery with no significant impact from new COVID-19 variants or waves. It also depends upon the virus’ impact on patient willingness to seek elective care, healthcare staffing issues and more.

“I am very pleased with the significant efforts of the Nevro team to serve our customers and patients, and execute on our plans throughout 2022,” said Grossman. “We continued to move our business forward and see encouraging signs of recovery, which we expect to continue throughout 2023.

“I’m very pleased with the building blocks that are now in place for attractive growth and leverage going forward, and we believe the challenges to our market will gradually but steadily improve throughout 2023.”

Shares of NVRO were down more than 5% at $37.54 apiece in morning trading today. MassDevice‘s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — rose more than 7%.

Filed Under: Business/Financial News, Featured, Implants, MassDevice Earnings Roundup, Neurological, Neuromodulation/Neurostimulation, News Well, Pain Management, Wall Street Beat Tagged With: Nevro Corp., Personnel Moves

More recent news

  • Vicarious Surgical inks surgical robot collab with hospital, eyes first clinical patients
  • Bioliberty launches hub for soft-robotic wearable devices
  • Zynex submits laser pulse oximeter to FDA
  • Roche invests $550M to make Indianapolis a CGM manufacturing hub
  • Product liability lawsuits target Medtronic, Boston Scientific spinal cord stim tech

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at [email protected].

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy